The year of 2022 for "Theragnostic Imaging"

In 2022, the group focused on advancing the understanding of radionuclide therapies and improving dosimetry methods. A total of eight publications were produced, including both original research and a review paper on radionuclides for targeted therapy. Notable studies included dosimetric studies of 177Lu-lilotomab satetraxetan in non-Hodgkin lymphoma and contributions to the EANM dosimetry committee’s recommendations for 177Lu-labelled ligands.

Presentations were delivered at key international and national conferences. Highlights include invited talks at the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI), covering topics such as first-in-human dosimetry, the biodistribution of radium-224, and imaging advancements with Lead-212. Several national talks also focused on dosimetry for alpha-particles and PRRT.

The year also involved continued mentoring of graduate students, with one doctoral student and one master’s student successfully completing their theses under the group’s supervision. The group participated in abstract committees for both the EANM 2023 and NACP 2023 conferences, as well as chaired sessions at EANM 2022.

Overall, 2022 was a year of productive research dissemination and mentorship, with significant contributions to both the scientific community and education.